BioSpace News Archive

Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that it has submitted to the U.S. Food and Drug Administration a 505(b)(2) New Drug Application for its novel injectable formulation of cosyntropin (synthetic adrenocorticotropic hormone, or ACTH) depot with its partner, West Therapeutic Development, LLC. The application seeks approval for the use of this product as a diagnostic drug in the screening of patients presumed to have adrenocortical insufficiency.

Verastem, Inc. announced the grant of options to purchase 239,000 shares of its common stock to eight new employees and 50,000 restricted stock units to one new employee.

Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 26, 2019 to file lead plaintiff applications in a securities class action lawsuit against CVS Health Corporation (NYSE: CVS), if they purchased the Company’s securities between May 21, 2015 and February 20, 2019, inclusive (the “Class Period”).

The U.S. Food and Drug Administration is updating the public on the agency’s ongoing investigation surrounding the recent voluntary recalls of multiple generic angiotensin II receptor blocker (ARB) drug products used to treat high blood pressure and heart failure.

Economic activity in the manufacturing sector expanded in February, and the overall economy grew for the 118th consecutive month, say the nation’s supply executives in the latest Manufacturing ISM® Report On Business®.

Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the presentation of a new post hoc analysis of data from a Phase 2a, proof-of-concept study of GBR 830 at the American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.

Joycare Pediatric Day Health Center announced today the appointment of its first CEO, Micah Grossman. Mr. Grossman will drive all growth and expansion initiatives while working to develop and promote operational efficiencies.

The U.S. Hemp Authority today announced the first awards of its Certification Seal to 13 outstanding companies that have met the stringent standards the industry laid out for quality and safety.

Teva Pharmaceutical Industries Ltd., announced the launch of an authorized generic of Flector®1 Patch, 1.3 %, in the U.S.

Dicerna Pharmaceuticals, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 238,000 shares of common stock to be distributed among six new employees, with a grant date of March 1, 2019.